Barclays
RUBY

Barclays’s Rubius Therapeutics, Inc RUBY Stock Holding History

Barclays’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,643
Closed -$42K – 5412
2022
Q1 		$42K Sell
7,643
-48,104
-86% -$306K ﹤0.01% 4186
2021
Q4 		$540K Buy
55,747
+35,566
+176% +$493K ﹤0.01% 3172
2021
Q3 		$360K Buy
20,181
+14,173
+236% +$308K ﹤0.01% 3345
2021
Q2 		$146K Sell
6,008
-24,461
-80% -$612K ﹤0.01% 3685
2021
Q1 		$807K Buy
30,469
+9,898
+48% +$145K ﹤0.01% 2901
2020
Q4 		$157K Sell
20,571
-7,106
-26% -$42.2K ﹤0.01% 3907
2020
Q3 		$140K Sell
27,677
-3,543
-11% -$18.8K ﹤0.01% 4057
2020
Q2 		$187K Buy
31,220
+15,535
+99% +$91.7K ﹤0.01% 4118
2020
Q1 		$70K Sell
15,685
-19,315
-55% -$143K ﹤0.01% 5016
2019
Q4 		$333K Buy
35,000
+13,965
+66% +$135K ﹤0.01% 4633
2019
Q3 		$164K Sell
21,035
-8,778
-29% -$102K ﹤0.01% 5111
2019
Q2 		$468K Buy
29,813
+18,982
+175% +$306K ﹤0.01% 4374
2019
Q1 		$195K Buy
10,831
+10,631
+5,316% +$163K ﹤0.01% 4846
2018
Q4 		$3K Sell
200
-4,355
-96% -$79.4K ﹤0.01% 6654
2018
Q3 		$109K Buy
+4,555
New +$104K ﹤0.01% 5472

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's RUBY Position: Q2 2022 in Review

Barclays sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 7,643 shares — an estimated $42K sold.

Barclays first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $807K in Q1 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Barclays reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 7,643 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $42K.
  • Barclays first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
  • Barclays's Rubius Therapeutics, Inc position peaked at $807K in Q1 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.